284 related articles for article (PubMed ID: 12379854)
1. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.
Kurose K; Gilley K; Matsumoto S; Watson PH; Zhou XP; Eng C
Nat Genet; 2002 Nov; 32(3):355-7. PubMed ID: 12379854
[TBL] [Abstract][Full Text] [Related]
2. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer.
Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
Genes Chromosomes Cancer; 2002 Sep; 35(1):74-80. PubMed ID: 12203792
[TBL] [Abstract][Full Text] [Related]
3. Genetic mutual relationship between PTEN and p53 in gastric cancer.
Oki E; Tokunaga E; Nakamura T; Ueda N; Futatsugi M; Mashino K; Yamamoto M; Watanabe M; Ikebe M; Kakeji Y; Baba H; Maehara Y
Cancer Lett; 2005 Sep; 227(1):33-8. PubMed ID: 16051030
[TBL] [Abstract][Full Text] [Related]
4. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.
Freihoff D; Kempe A; Beste B; Wappenschmidt B; Kreyer E; Hayashi Y; Meindl A; Krebs D; Wiestler OD; von Deimling A; Schmutzler RK
Br J Cancer; 1999 Feb; 79(5-6):754-8. PubMed ID: 10070865
[TBL] [Abstract][Full Text] [Related]
5. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas.
Bose S; Wang SI; Terry MB; Hibshoosh H; Parsons R
Oncogene; 1998 Jul; 17(1):123-7. PubMed ID: 9671321
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.
Feilotter HE; Coulon V; McVeigh JL; Boag AH; Dorion-Bonnet F; Duboué B; Latham WC; Eng C; Mulligan LM; Longy M
Br J Cancer; 1999 Feb; 79(5-6):718-23. PubMed ID: 10070859
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
Rhei E; Kang L; Bogomolniy F; Federici MG; Borgen PI; Boyd J
Cancer Res; 1997 Sep; 57(17):3657-9. PubMed ID: 9288766
[TBL] [Abstract][Full Text] [Related]
8. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
Patocs A; Zhang L; Xu Y; Weber F; Caldes T; Mutter GL; Platzer P; Eng C
N Engl J Med; 2007 Dec; 357(25):2543-51. PubMed ID: 18094375
[TBL] [Abstract][Full Text] [Related]
9. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
[TBL] [Abstract][Full Text] [Related]
10. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
[TBL] [Abstract][Full Text] [Related]
11. Presence of allelic loss and PTEN mutations in malignant gliomas from Malay patients.
Zainuddin N; Jaafar H; Isa MN; Abdullah JM
Med J Malaysia; 2004 Oct; 59(4):468-79. PubMed ID: 15779579
[TBL] [Abstract][Full Text] [Related]
12. A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease.
Vega A; Torres J; Torres M; Cameselle-Teijeiro J; Macia M; Carracedo A; Pulido R
J Invest Dermatol; 2003 Dec; 121(6):1356-9. PubMed ID: 14675182
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of the PTEN gene is a common molecular change in breast cancer.
García JM; Silva J; Peña C; Garcia V; Rodríguez R; Cruz MA; Cantos B; Provencio M; España P; Bonilla F
Genes Chromosomes Cancer; 2004 Oct; 41(2):117-24. PubMed ID: 15287024
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
[TBL] [Abstract][Full Text] [Related]
15. Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation.
Reifenberger J; Rauch L; Beckmann MW; Megahed M; Ruzicka T; Reifenberger G
Br J Dermatol; 2003 May; 148(5):1040-6. PubMed ID: 12786840
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
17. PTEN: one gene, many syndromes.
Eng C
Hum Mutat; 2003 Sep; 22(3):183-98. PubMed ID: 12938083
[TBL] [Abstract][Full Text] [Related]
18. PTEN promoter is methylated in a proportion of invasive breast cancers.
Khan S; Kumagai T; Vora J; Bose N; Sehgal I; Koeffler PH; Bose S
Int J Cancer; 2004 Nov; 112(3):407-10. PubMed ID: 15382065
[TBL] [Abstract][Full Text] [Related]
19. PTEN mutations in uterine sarcomas.
Amant F; de la Rey M; Dorfling CM; van der Walt L; Dreyer G; Dreyer L; Vergote I; Lindeque BG; Van Rensburg EJ
Gynecol Oncol; 2002 Apr; 85(1):165-9. PubMed ID: 11925138
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas.
Gimm O; Chi H; Dahia PL; Perren A; Hinze R; Komminoth P; Dralle H; Reynolds PR; Eng C
J Clin Endocrinol Metab; 2001 Apr; 86(4):1801-5. PubMed ID: 11297621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
